方法：对 2010 年至 2022 年期间接受抗血管内皮生长因子（vascular endothelial growth factor，VEGF）治疗的新生血管性 AMD 患者进行回顾性研究。患者被分为长期失访组（失访时间超过 6 个月）、短期失访组（失访时间为 2 个月至不足 6 个月）和持续随访组。研究人员对各 ...

免疫检查点抑制剂（ICI）治疗癌症时会引发炎症性关节炎（ICI-IA）等不良反应，却缺乏有效治疗靶点。研究人员开展了对 ICI-IA 患者细胞因子的研究，发现 VEGF-A 和 TNF α 水平升高与 ICI-IA 相关，这些细胞因子或可作为生物标志物及治疗靶点。

BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.

The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

Leap Therapeutics' Phase 2 trial data show sirexatamab boosts response rates and survival in MSS colorectal cancer, with ...

The entire 36-week data for the remaining subjects in the trial is anticipated in the second quarter of this year.

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024.

The following is a summary of “Incidence and reasons for discontinuation of anti-VEGF treatment in neovascular age-related macular degeneration,” published in the March 2025 issue of British Journal ...

Conference Call to discuss Updated Data from Part B of the DeFianCe Study March 26, 2025 8:00 AM ET. Company Participants. Douglas Onsi - President ...

Leap Therapeutics (LPTX) presented updated preliminary data from Part B of the DeFianCe study, a Phase 2, open-label, global study of ...

Ended Q4 with $168.1M of cash and cash equivalents and believes current cash will support current and planned operations into 2026. “In ...

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today presented updated preliminary data from Part B of the DeFianCe ...